剂量递增放疗对比标准放疗治疗胶质母细胞瘤:22项前瞻性试验的系统综述与Meta分析
该系统综述与Meta分析纳入22项已发表研究、共2198例新诊断胶质母细胞瘤患者,其中507例接受剂量递增放疗(DE-RT)。结果显示,单纯DE-RT较单纯标准放疗(SoC-RT)提高1年总生存(46.3% vs 23.4%,P=.02)和无进展生存(17.9% vs 5.3%,P=.02);但DE-RT联合替莫唑胺(TMZ)与SoC-RT联合TMZ相比,1年OS和PFS均无显著差异,且未发现基于MGMT状态的差异获益。
要点
- 单纯DE-RT较单纯SoC-RT显著改善1年OS和PFS。
- DE-RT联合TMZ与SoC-RT联合TMZ的1年OS和PFS无显著差异。
- MGMT甲基化或非甲基化患者中DE-RT联合TMZ均未见显著OS获益。
核心结论
- 单纯DE-RT较单纯SoC-RT获得更优的PFS和OS。
- DE-RT联合TMZ较SoC-RT联合TMZ未改善结局。
- 未发现基于MGMT状态的差异获益。
研究设计与样本
- 国际系统综述与Meta分析,纳入22项已发表前瞻性研究。
- 共2198例新诊断胶质母细胞瘤患者,其中507例接受DE-RT。
- 采用PICOS/PRISMA/MOOSE选择标准,主要终点为1年OS,次要终点为1年PFS。
- 使用Knapp-Hartung校正的随机效应Meta分析、反正弦变换和限制性最大似然法。
- 采用Meta回归以Wald型检验比较治疗和病理特征。
主要发现
- 单纯DE-RT较单纯SoC-RT的1年OS为46.3% vs 23.4%(P=.02)。
- 单纯DE-RT较单纯SoC-RT的1年PFS为17.9% vs 5.3%(P=.02)。
- DE-RT+TMZ与SoC-RT+TMZ的1年OS为73.2% vs 64.4%(P=.23)。
- DE-RT+TMZ与SoC-RT+TMZ的1年PFS为44.5% vs 44.3%(P=.33)。
- MGMT甲基化患者中DE-RT+TMZ与SoC-RT+TMZ的1年OS为83.2% vs 73.2%(P=.23);非甲基化患者为72.6% vs 50.6%(P=.16)。
关键数值与推荐
- DE-RT依据等效剂量计算定义。
- 结局与比较按是否接受TMZ及MGMT状态进行亚组划分。
临床怎么用
- 单纯放疗背景下,DE-RT较SoC-RT显示生存优势。
- 联合TMZ时,DE-RT未较SoC-RT带来额外获益。
- MGMT状态未显示可指导DE-RT选择的差异获益。
- 需未来研究明确最可能从DE-RT获益的亚组。
局限性
- 纳入研究均为已发表的前瞻性试验,可能存在发表偏倚。
- DE-RT组样本量相对较小(507例)。
- 需进一步研究确定DE-RT获益亚组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Limited evidence is available on the utility of dose-escalated radiation therapy (DE-RT) with or without temozolomide (TMZ) versus standard-of-care radiation therapy (SoC-RT) for patients with newly diagnosed glioblastoma multiforme. We performed a systematic review/meta-analysis to compare overall survival (OS) and progression-free survival (PFS) between DE-RT and SoC-RT. METHODS AND MATERIALS: We used a Population, Intervention, Control, Outcomes, Study Design/Preferred Reporting Items for Systematic Reviews and Meta-analyses/Meta-analysis of Observational Studies in Epidemiology selection criterion to identify studies. The primary and secondary outcomes were 1-year OS and 1-year PFS, respectively. Outcomes and comparisons were subdivided based on receipt of TMZ and MGMT status. DE-RT was defined based on equivalent dose calculations. Random effects meta-analyses using the Knapp-Hartung correction, arcsine transformation, and restricted maximum likelihood method were conducted. Meta-regression was used to compare therapeutic (eg, DE-RT or TMZ) and pathologic characteristics (eg, MGMT methylation status) using the Wald-type test. RESULTS: Across 22 published studies, 2198 patients with glioblastoma multiforme were included; 507 received DE-RT. One-year OS after DE-RT alone was higher than SoC-RT alone (46.3% vs 23.4%; P = .02) as was 1-year PFS (17.9% vs 5.3%; P = .02). No significant difference in 1-year OS (73.2% vs 64.4%; P = .23) or 1-year PFS (44.5% vs 44.3%; P = .33) between DE-RT + TMZ and SoC-RT + TMZ was noted. No difference in 1-year OS was noted between DE-RT + TMZ and SoC-RT + TMZ in either MGMT methylated (83.2% vs 73.2%; P = .23) or MGMT unmethylated (72.6% vs 50.6%; P = .16) patients. CONCLUSIONS: DE-RT alone resulted in superior PFS and OS versus SoC-RT alone. DE-RT + TMZ did not lead to improved outcomes versus SoC-RT + TMZ. No differential benefit based on MGMT status was found. Future studies are warranted to define which subgroups benefit most from DE-RT.
引用
- Singh R, Lehrer EJ, Wang M, et al. Dose Escalated Radiation Therapy for Glioblastoma Multiforme: An International Systematic Review and Meta-Analysis of 22 Prospective Trials. Int J Radiat Oncol Biol Phys. 2021. PMID: 33991621. doi:10.1016/j.ijrobp.2021.05.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。